In Vitro ADME/DMPK Studies
With decades of drug metabolism, drug-drug interactions (DDI) and related expertise, BioIVT’s experts can provide you with the right studies to understand the properties and potential risks of your compound when it’s most critical for your program.
Drug Metabolism and Interaction Assays
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
BioIVT's comprehensive ADME services combine the expertise of XenoTech, Cypex, ZenBio and others to provide a full spectrum of drug metabolism, drug-drug interactions (DDI), and related assays, bioanalysis or consulting services, tailored to your therapeutic, stage of development and program goals. Available services include:
- Metabolite ID/Characterization
- Metabolic Stability
- Reaction Phenotyping
- Transporter Inhibition & Substrate
- Enzyme Inhibition & Induction
- Cell Permeability
- RBC Partitioning & Plasma Protein Binding
- Lysosomal Trapping
- Hepatotoxicity
- Hepatobiliary Disposition
- Antioxidant Assays
- Bioanalysis
- Consulting (Gap Analysis, Due Diligence, Writing/Presentations, etc.)
- And more
ADME/DDI challenges and strategies for emerging modalities including a PROTAC case study
Tuesday, September 29 at 16:00 BST | 17:00 CEST | 11:00 EDT | 08:00 PDT
Not all drug candidates behave like traditional small molecules. As modalities such as PROTACs, oligonucleotides, antibody-drug conjugates (ADCs), and peptides gain momentum, researchers are increasingly challenged to apply established absorption, distribution, metabolism, and excretion (ADME) and drug-drug interaction (DDI) approaches in new ways.
In vitro ADME and DDI studies are critical tools for identifying safety and potential interaction risks in early development. When applied appropriately, they can also help address the unique challenges associated with emerging modalities, including PROTACs and other protein degraders.
In this SelectScience webinar, discover how adapting test conditions and using complementary in vitro systems can improve understanding of metabolic clearance, biotransformation pathways, and DDI risk assessment. Dr. Tina Mueller, Scientific Advisor for ADME-Tox Services at BioIVT, will demonstrate applying these concepts with a case study using BioIVT-generated data from evaluating two commercially available PROTACs, ARV-825 and JNJ-1013. She will also discuss practical strategies for navigating common development challenges and generating data that supports informed decision-making and regulatory alignment.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
Cost: Free to attend
Location: Online
Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
